Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts

BACKGROUND: In the Phase III KRONOS study, triple therapy with budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI) was shown to reduce exacerbations and improve lung function versus glycopyrronium/formoterol fumarate dihydrate (GFF) MDI in patients with moderate-to-very seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Muro, Shigeo, Sugiura, Hisatoshi, Darken, Patrick, Dorinsky, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240276/
https://www.ncbi.nlm.nih.gov/pubmed/34182998
http://dx.doi.org/10.1186/s12931-021-01773-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240276/
https://www.ncbi.nlm.nih.gov/pubmed/34182998
http://dx.doi.org/10.1186/s12931-021-01773-1

Ejemplares similares